Product news from 09/09 News Brief

Share this article:

Takeda Pharmaceuticals North America announced that the FDA has approved the New Drug Application for ACTOplus Met for the treatment of type 2 diabetes.

Cephalon has entered into an agreement with McNeil Consumer & Specialty Pharmaceuticals to co-promote Attenace (modafinil) Tablets. Attenace is Cephalon's proprietary dosage form of modafinil, which is awaiting FDA approval for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents. 

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.